Roche posts IMpower030 results: atezolizumab before surgery in resectable lung cancer
Hoffmann-La Roche posted results for the Phase 3 IMpower030 trial on October 9, 2026. In the Stage IIB-IIIB wild-type group, median event-free survival was 34.92 months on placebo and 62.78 months on atezolizumab, both plus chemotherapy.
Machine-summarized from the primary sources listed below; not independently reported. How we use automation
Hoffmann-La Roche has posted results for IMpower030, a Phase 3 study of atezolizumab before surgery in people with resectable non-small cell lung cancer (NSCLC). The trial registry record for NCT03456063 lists the results as first posted on October 9, 2026. In the Stage IIB-IIIB wild-type group, the record reports median event-free survival of 34.92 months with placebo plus chemotherapy and 62.78 months with atezolizumab plus chemotherapy.
What the record says about the design
The record calls the study a Phase III, double-blinded, multicenter, randomized study of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy. It enrolled people with resectable Stage II, IIIA or select IIIB NSCLC. Participants were randomized 1:1.
Participants in the atezolizumab arm received atezolizumab 1200 mg by intravenous infusion on Day 1 of each cycle, with platinum-based chemotherapy, for 4 cycles before surgical resection. They then received adjuvant atezolizumab 1200 mg on Day 1 of each cycle for 16 cycles, or until unacceptable toxicity, disease recurrence, death, or a decision to stop. The control arm received placebo with the same kind of chemotherapy. One cycle is 21 days.
The record lists enrollment as 453. Its recruitment details say 451 participants took part at 120 investigative sites across 24 countries from 24 April 2018 to 31 December 2025. The record lists primary completion as October 1, 2025 and completion as December 31, 2025.
The primary outcomes
The record lists two primary outcomes. Both are event-free survival assessed by an independent review facility (IRF). The record defines it as the time from randomization to disease progression that precluded surgery, local or distant recurrence, or death from any cause.
In the Stage IIB-IIIB wild-type population, 201 participants received placebo plus chemotherapy and 196 received atezolizumab plus chemotherapy. The record defines this population as participants with Stage IIB-IIIB disease who had no known EGFR activating mutation or known ALK fusion oncogene. Median event-free survival was:
- placebo plus chemotherapy: 34.92 months (95% confidence interval 24.57 to 63.80)
- atezolizumab plus chemotherapy: 62.78 months (95% confidence interval 41.43 to not estimable)
The record gives a hazard ratio of 0.77 (95% confidence interval 0.58 to 1.02) and a log-rank p-value of 0.0704.
In the EGFR/ALK wild-type intent-to-treat population, 221 participants received placebo plus chemotherapy and 219 received atezolizumab plus chemotherapy. Median event-free survival was 43.86 months (95% confidence interval 28.02 to 63.80) on placebo and 67.15 months (95% confidence interval 49.15 to not estimable) on atezolizumab. The record gives a hazard ratio of 0.75 (95% confidence interval 0.57 to 0.98).
The record says the upper limit of the confidence interval was not estimable because too few participants had events.
Response at surgery and survival
The record lists two secondary outcomes measured at surgery in the Stage IIB-IIIB wild-type population. It defines the pathological complete response rate as the percentage of participants with an absence of any viable primary tumor cells at the time of surgical resection in the primary tumor and all sampled lymph nodes. Participants who did not undergo surgery counted as non-responders.
The pathological complete response rate was 8.5% (95% confidence interval 5.00 to 13.20) with placebo plus chemotherapy and 29.6% (95% confidence interval 23.30 to 36.51) with atezolizumab plus chemotherapy. The record gives a difference of 21.13 percentage points (95% confidence interval 13.68 to 28.59).
The record defines the major pathological response rate as the percentage of participants with 10% or less residual viable tumor cells in the primary tumor. The rate was 24.4% (95% confidence interval 18.61 to 30.92) with placebo and 53.6% (95% confidence interval 46.33 to 60.71) with atezolizumab. The record gives a difference of 29.19 percentage points (95% confidence interval 20.03 to 38.36).
For overall survival in the same population, the record lists a median of 81.74 months (95% confidence interval 66.79 to not estimable) with placebo plus chemotherapy. The median was not estimable with atezolizumab plus chemotherapy because too few participants had events. The hazard ratio is 0.79 (95% confidence interval 0.57 to 1.09).
Safety counts in the record
The record reports adverse events for the safety population: 224 participants who received placebo plus chemotherapy and 226 who received atezolizumab plus chemotherapy. The record lists the number of participants with adverse events as 222 on placebo and 226 on atezolizumab. It lists the number of participants with serious adverse events as 72 on placebo and 105 on atezolizumab.
Roche posted these figures as summary data in the registry. The record is the sponsor's report, and this story reports its numbers as posted.